Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel
NASDAQ:PHVS

Pharvaris Q2 2025 Earnings Report

Pharvaris logo
$29.68 -0.43 (-1.43%)
Closing price 04:00 PM Eastern
Extended Trading
$29.62 -0.05 (-0.19%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Pharvaris EPS Results

Actual EPS
-$0.94
Consensus EPS
-$0.87
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Pharvaris Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pharvaris Announcement Details

Quarter
Q2 2025
Date
8/12/2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Pharvaris' Q2 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Pharvaris' Q2 2025 Press ReleasePress Release
(8-K)

Pharvaris Earnings Headlines

Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $115,168.10 in Stock
May 4 at 5:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30757899
Pharvaris (NASDAQ:PHVS) Insider Sells $111,296.00 in Stock
May 4 at 5:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30757901
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 7 at 1:00 AM  |  Brownstone Research (Ad)
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
April 30, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/04/29/for-pharvaris-investors-the-director-s-sale-matters-less-than-what-s-coming-next/
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3276834/0/en/Evidence-Supporting-Combined-Use-of-Deucrictibant-IR-with-Deucrictibant-XR-Presented-at-CIIC-Spring-2026-Conference.html
Pharvaris N.V. (PHVS) Presents at CIIC Spring 2026 Conference - Slideshow
April 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891541-pharvaris-n-v-phvs-presents-at-ciic-spring-2026-conference-slideshow
See More Pharvaris Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email.

About Pharvaris

Pharvaris (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials. Pharvaris is also developing an on-demand version of its kallikrein inhibitor to provide patients with an acute treatment option. Both candidates represent the company’s effort to offer fully oral alternatives to current injectable therapies.

Founded in 2016 and headquartered in Leiden, the Netherlands, Pharvaris maintains a presence in the United States to support clinical development and regulatory engagement. Since completing its initial public offering on the NASDAQ in 2020, the company has expanded its research partnerships and scaled its operations to prepare for potential commercialization.

Pharvaris is led by an experienced management team with deep expertise in rare disease drug development, medicinal chemistry and clinical operations. The company’s board and advisory committees include professionals with backgrounds in immunology, hematology and regulatory affairs, guiding its strategy toward delivering innovative treatments to patients worldwide.

View Pharvaris Profile
Earnings Tools